Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | An overview of mouse models to study cell therapies for cancer

Juliane Mietz, University Of Zurich, Zurich, Switzerland, provides an overview of mouse models currently in use for the pre-clinical study of immunotherapies, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX). CDX models are derived from established and easily accessible cell lines, which is beneficial for monitoring tumor growth and assessing chimeric antigen receptor (CAR) T-cell efficacy. PDX models consist of tissue from the patient’s tumor and will retain the pathophysiology of the patient. However the aforementioned models are modelled in immunocompromised mice and humanized mice models consisting of hematopoietic progenitor cells (HPCs) derived from fetal liver tissue or cord blood represent an alternative. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.